On April 29, XtalPi Holdings (02228.HK) saw a notable rally, with its intraday gain once exceeding 8%. As of the time of writing, the stock was trading at HK$9.14, up HK$0.66 or 7.78%. It touched a high of HK$9.24 during the session, with turnover reaching approximately HK$612 million and volume of about 68.97 million shares, indicating a significant expansion in trading activity compared to previous periods.

(Image Source: uSMART HK app)

AI Drug Pipeline Reaches Key Milestone, Project Nears Clinical Stage

On the news front, the company disclosed at the 2026 Guangdong AI Application Matchmaking Conference that its AI-driven autonomous research platform has advanced a candidate drug, SIGX2649, through preclinical studies. The company plans to submit Investigational New Drug (IND) applications simultaneously to regulatory authorities in both China and the United States, marking the project’s imminent transition into clinical development.

In addition, related findings are set to be presented at an international oncology conference, which is expected to further boost market attention. For XtalPi, whose core focus lies in AI-driven drug discovery, advancing its pipeline to the IND stage signals a shift from “validation of R&D capabilities” toward “realization of clinical value.”

Rare Target with Differentiated Profile Drives Market Repricing Potential

In terms of product characteristics, SIGX2649 is a pan-TEAD inhibitor targeting a key node in the HIPPO signaling pathway. This area currently lacks commercially approved drugs globally, underscoring its relative scarcity.

Preclinical data suggest that the candidate demonstrates inhibitory activity across multiple TEAD subtypes, achieving a balance between anti-tumor efficacy and safety, while also showing potential advantages in reducing nephrotoxicity.

Moreover, its potential in combination therapies provides room for future expansion into broader indications. The market generally believes that, if clinical development proceeds smoothly, such candidates with “first-in-class” or “best-in-class” potential could tap into the vast solid tumor market.

Platform Capabilities Continue to Validate as “AI + Automation” Enters Monetization Phase

Behind this progress lies the continued validation of the company’s platform capabilities. XtalPi integrates AI algorithms with automated laboratory systems to enhance molecular screening efficiency and shorten R&D timelines.

As projects advance toward IND submission and clinical stages, market expectations are strengthening for the company’s transition from a “technology platform” to a “product-output platform.” Compared with traditional biotech firms reliant on a single pipeline, this multi-project parallel development model offers, to some extent, greater resilience against risk.

How to Buy XtalPi Holdings on uSMART

After logging into the uSMART HK app, click the “Search” button in the top-right corner of the page, enter the ticker code(02228.HK), and navigate to the details page to view transaction details and historical trends. Click the “Trade” button in the bottom-right corner, select the trade type, and submit your order after filling in the transaction conditions.

(Image Source: uSMART HK app)